Triamcinolone Acetonide as an Adjuvant to Pre-emptive Scalp Infiltration for Relief of Post-craniotomy Pain in Adults
- Disease/Condition
- Pain, Postoperative
- Drug/Device/Intervention
- The TR group
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Beijing Tiantan Hospital
- Location
- Beijing, China
- Phase
- Phase 4
- Start date
- Sep 25, 2023
- End date
- Dec 31, 2023
- Enrollment
- 130 participants
Cumulative sufentanil consumption within 48 hours postoperatively
Pain is common for the first 2 days after major craniotomy. A majority of patients would
 suffer from moderate-to-severe postoperative pain after undergoing craniotomy. Inadequate
 analgesia induced sympathetically mediated hypertension may lead to an increased risk for
 post-operative complications. Adequate pain control is essential for patients' prognosis and
 their postoperative life quality. Pain after craniotomy derives from the scalp and
 pericranial muscles. Local anesthetics administered around the incision have been performed
 clinically. However, some studies revealed that the analgesic effect of local anesthetics was
 not unsatisfactory due to its short pain relief duration. Pain is common for the first 2 days
 after major elective intracranial surgery, and the relatively short analgesic time of scalp
 infiltration does not seem to meet the requirements of craniotomy. Steroid such as
 triamcinolone acetonide as an adjuvant to local anesthetics intra-articular injected locally
 ameliorated pain intensity inarthroscopic knee surgery or total knee arthroplasty. However,
 there has not been reported about local application of triamcinolone acetonide on scalp
 infiltration. Thus, the investigators suppose that pre-emptive scalp infiltration with
 steroid (triamcinolone acetonide) plus local anesthetic (ropivacaine) could relieve
 postoperative pain after craniotomy in adults.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06069804
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06069804 through Pure Global AI's free database. This Phase 4 trial is sponsored by Beijing Tiantan Hospital and is currently Recruiting. The study focuses on Pain, Postoperative. Target enrollment is 130 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.